Peak BioNASDAQ: PKBO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 March 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$531.87 K
-99%vs. 3y high
3%vs. sector
-vs. 3y high
-vs. sector
-101%vs. 3y high
15%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Thu, 14 Nov 2024 14:30:00 GMT
$0.02(0.00%)

Dividend

No data over the past 3 years
$0.00$1.71 M

Analysts recommendations

Institutional Ownership

What type of business is Peak Bio?

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company's lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors. Peak Bio, Inc. is based in Pleasanton, California. As of November 14, 2024, Peak Bio, Inc. operates as a subsidiary of Akari Therapeutics, Plc.

What sector is Peak Bio in?

Peak Bio is in the Healthcare sector

What industry is Peak Bio in?

Peak Bio is in the Biotechnology industry

What country is Peak Bio from?

Peak Bio is headquartered in United States

When did Peak Bio go public?

Peak Bio initial public offering (IPO) was on 15 March 2021

What is Peak Bio website?

https://peak-bio.com

Is Peak Bio in the S&P 500?

No, Peak Bio is not included in the S&P 500 index

Is Peak Bio in the NASDAQ 100?

No, Peak Bio is not included in the NASDAQ 100 index

Is Peak Bio in the Dow Jones?

No, Peak Bio is not included in the Dow Jones index

When was Peak Bio the previous earnings report?

No data

When does Peak Bio earnings report?

Next earnings report date is not announced yet